JEREMY WALSTON, M.D.
Osteopathic Medicine at Hopkins Bayview Cir, Baltimore, MD

2014005, Feb 27, 2014

Mar 30, 2012

14/008585

Peter M. Abadir - Woodstock MD, US
Jeremy D. Walston - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

G01N 33/566, A61K 31/4184, A61K 31/4178, A61K 31/41

514381, 514394, 514397, 435 29, 435375

Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 ATR and ATR receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.

2013012, May 16, 2013

Nov 12, 2012

13/674197

The Johns Hopkins University - Baltimore MD, US
Dan E. Berkowitz - Baltimore MD, US
Lili Ayala Barouch - Ellicott City MD, US
Jeremy D. Walston - Baltimore MD, US

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

C12Q 1/02

424 852, 435 29

Provided herein are methods for treating, preventing or reducing age related vascular stiffness and impaired cardiovascular function in a subject comprising administering to the subject a therapeutic amount of IL-10 or an IL-10 agonist or pharmaceutical compositions comprising the same. Also included herein are methods for determining whether a biologically active agent can treat, prevent or reduce age related vascular stiffness and impaired cardiovascular function using an in vitro model in a IL-10 knockout IL-10(tm/tm) mouse which lacks IL-10 function.

5766851, Jun 16, 1998

May 19, 1995

8/446530

Alan R. Shuldiner - Columbia MD
Jeremy Walston - Baltimore MD
Kristi Silver - Baltimore MD
Jesse Roth - Baltimore MD

The Johns Hopkins University School of Medicine - Baltimore MD

C12Q 168, C12P 1934, C07H 2104

435 6

The present invention provides a novel polypeptide characterized by a non-conservative missense mutation, Trp64Arg, in the. beta. 3-adrenergic receptor (. beta. 3AR) that increases susceptibility to obesity and non-insulin dependent diabetes mellitus (NIDDM; type II diabetes). Also provided are methods of diagnosis and methods of treatment of subjects having or at risk of having type II diabetes/obesity.

5877283, Mar 2, 1999

Jun 15, 1998

/097562

Alan R. Shuldiner - Columbia MD
Jeremy Walston - Baltimore MD
Kristi Silver - Baltimore MD
Jesse Roth - Baltimore MD

The Johns Hopkins University School of Medicine - Baltimore MD

C07K 14435

530350

The present invention provides a novel polypeptide characterized by a non-conservative missense mutation, Trp64Arg, in the. beta. 3-adrenergic receptor (. beta. 3AR) that increases susceptibility to obesity and non-insulin dependent diabetes mellitus (NIDDM; type II diabetes). Also provided are methods of diagnosis and methods of treatment of subjects having or at risk of having type II diabetes/obesity.